kabutan

Nxera Pharma surges again, briefly hitting daily limit as partner Centessa to be acquired by Eli Lilly

Wed Apr 1, 2026 12:33 pm JST Catalyst

Nxera Pharma Co., Ltd. <4565> surged again, briefly hitting the daily limit up at \1,022, up \150 from the previous trading day. Partner company UK-based Centessa Pharmaceuticals announced on the 31st U.S. time that it would be acquired by U.S.-based Eli Lilly . Nxera holds rights to receive certain milestones and royalties related to Centessa's orexin 2 receptor (OX2) agonist series "cleminorexton/ORX750," "ORX142," and "ORX489," as well as a stake in Centessa, attracting strong buying interest.

The OX2 agonist series aims to treat a wide range of diseases related to sleep-wake regulation and other conditions. The series was jointly created by Nxera and Centessa under a partnership that grants Centessa access to Nxera's NxStaR (stabilized receptor) technology.

Source: MINKABU PRESS

Related Articles